Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists formetastatic disease. Similarly to cutaneousmelanoma, up to 50%of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.

Rossi, E., Maiorano, B. A., Pagliara, M. M., Maria Grazia Sammarco,, Tommaso, D., Martini, M., Rindi, G., Bria, E., Blasi, M. A., Tortora, G., Schinzari, G., Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma, <<FRONTIERS IN ONCOLOGY>>, 2019; 9 (april): 1-5. [doi:10.3389/fonc.2019.00232] [http://hdl.handle.net/10807/134546]

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Ernesto Rossi;Maiorano, Brigida Anna;Monica Maria Pagliara;Maurizio Martini;Guido Rindi;Emilio Bria;Maria Antonietta Blasi;Giampaolo Tortora;Giovanni Schinzari
2019

Abstract

Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists formetastatic disease. Similarly to cutaneousmelanoma, up to 50%of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.
eng
Rossi, E., Maiorano, B. A., Pagliara, M. M., Maria Grazia Sammarco,, Tommaso, D., Martini, M., Rindi, G., Bria, E., Blasi, M. A., Tortora, G., Schinzari, G., Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma, <>, 2019; 9 (april): 1-5. [doi:10.3389/fonc.2019.00232] [http://hdl.handle.net/10807/134546]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/134546
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 16
social impact